Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324608 | 1.00 | CKS1B (0.43) | CKS1BSKP1SKP2EPHX1EPHX2 | |
| SCHEMBL11909488 | 1.00 | CKS1B (0.43) | CKS1BSKP1SKP2EPHX1EPHX2 | |
| SCHEMBL13549321 | 0.81 | EPHX1 (0.59) | CKS1BSKP1SKP2EPHX1EPHX2 | |
| SCHEMBL3104385 | 0.80 | KDM4E (0.52) | EPHX1SSTR4KDM4EPKMALDH1A1 | |
| SCHEMBL12046261 | 0.80 | KDM4E (0.52) | EPHX1SSTR4KDM4EPKMALDH1A1 | |
| SCHEMBL3089931 | 0.80 | KDM4E (0.52) | EPHX1SSTR4KDM4EPKMALDH1A1 | |
| SCHEMBL30120837 | 0.78 | DRD2 (0.44) | EPHX1EPHX2KCNH2KDM4EPKM | |
| SCHEMBL23581899 | 0.77 | ALDH1A1 (0.39) | EPHX1EPHX2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL13752398 | 0.76 | DPP8 (0.41) | CKS1BSKP1SKP2EPHX1EPHX2 | |
| SCHEMBL9431190 | 0.75 | TDP1 (0.52) | CKS1BSKP1SKP2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | CKS1B 2649/4885SKP1 4240/4885SKP2 2806/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | CKS1B 1345/4885SKP1 1252/4885SKP2 1219/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | CKS1B 2654/4885SKP1 4016/4885SKP2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.